#Surgpath #Pathresidents #Pathtwitter A human of indeterminate age and health status presents to a local clinic with a mass in one of his or her bodily organs, which is excised. #Pathresidents: Diagnosis? Benign? Malignant?

Renal Medullary Carcinoma (RMC): highly aggressive tumor in patients with sickle cell trait. 🔬 Infiltrative growth with tubuloreticular and gland-like structures. Pleomorphic nuclei w/ prominent nucleoli. Brisk inflam infiltrate. Associated w/ necrosis and loss of SMARCB1/INI1

Need an update on the molecular pathology of genitourinary malignancies? Happy to share this outstanding review article, just published in the June issue of Surgical Pathology Clinics (PMID: 42091277), written by Professor Alessia Cimadamore @AlessiaCim   Over the past decade, remarkable advances in our understanding of genitourinary tumor biology have provided critical insights into the molecular and cellular pathways driving tumor initiation, progression, and therapeutic resistance. This evolving knowledge has not only refined our understanding of oncogenesis but has also identified important therapeutic vulnerabilities that can be leveraged for precision oncology.   By unraveling the complex interplay of signaling pathways, genomic alterations, and tumor microenvironmental factors, investigators continue to uncover novel drug targets and develop more effective, personalized treatment strategies for patients with GU malignancies.   Full article is available at the following link surgpath.theclinics.com/arti…

🚨 ISUP Presents..... 🔬 Dr. Bogdan Czerniak on “The Mystery of Cancer Initiation: Lessons from Bladder Carcinogenesis” 📅 24 June 2026 at 1pm EST via Zoom Register here: us06web.zoom.us/webinar/regi…

Excited to share two recent high-impact publications from Dr. Zhiping Wang’s lab, and truly honored to be part of these important studies advancing the landscape of precision oncology and FGFR3-targeted therapy in bladder cancer. In our Advanced Science study (PMID: 41168906, journal impact factor, 14), Dr. Wang and colleagues developed a novel FGFR3-targeting antibody–drug conjugate (ADC) delivering a potent camptothecin derivative (A2) directly to tumor cells. Beyond precise targeting, this work uncovers a compelling mechanism - activation of the cGAS - STING pathway, linking targeted therapy with innate immune signaling. The ADC demonstrated strong efficacy in patient-derived organoids and xenograft models, including chemotherapy-resistant disease, with a favorable safety profile. Complementing this, our Journal of Nanobiotechnologystudy (PMID: 41275281, journal impact factor, 12) introduces a precision nanotherapeutic platform enabling ultrasound-triggered intratumoral generation of cytotoxic agents. This innovative system integrates sonodynamic therapy, redox modulation, and programmed cell death (including pyroptosis), achieving spatially controlled tumor targeting while minimizing systemic toxicity. Together, these studies highlight key advances in bladder cancer therapeutics:
• Transition from conventional targeting to precision delivery platforms (ADC, nanomedicine)
• Integration of mechanistic biology with therapeutic design (STING activation, oxidative stress, pyroptosis)
• Overcoming resistance through multimodal and microenvironment-responsive strategies
• Expanding the clinical relevance of FGFR3 as a key actionable target Precision oncology is clearly entering a new phase -driven not only by molecular targets, but by innovative therapeutic engineering and deeper biologic insight. Grateful to be part of these outstanding collaborative efforts in advancing precision care of bladder cancer patients.

Please join the inaugural Grignon Award Lecture on May 5, delivered by distinguished professor Dan Berney. @daniel_berney Registration is free.

Happy to share this comprehensive review on Genomic Profiling of Upper Tract Urothelial Carcinoma (UTUC), authored by Professor Ali Amin (PMID: 40820359). Upper tract urothelial carcinoma remains a clinically important yet comparatively understudied malignancy, making this a timely and valuable contribution to the field. This review highlights that while UTUC and Urothelial carcinoma of the bladder share many genetic alterations, they often differ in frequency and biologic context. These genomic differences may help explain distinct phenotypic and clinical behaviors, supporting the concept that UTUC and bladder cancer, despite similarities, are biologically different diseases that require disease-specific approaches. The article also emphasizes the urgent need for large, dedicated next-generation sequencing studies focused specifically on UTUC across diverse patient populations, rather than combining data with bladder tumors. Better genomic characterization will help guide precision oncology, improve biomarker-driven treatment decisions, and support standardized testing strategies. Particularly important areas for future study include therapeutically relevant alterations such as ERBB2, ERCC2, mismatch repair–related and Lynch syndrome–associated UTUC, as well as newly identified variants of uncertain significance. Check it out: tandfonline.com/doi/abs/10.1… or doi.org/10.1080/14737159.202…

Excited to share this article from our lab, now out in JoVE, entitled "Visualization and Quantitative Analysis of Genotoxin-induced PARP1/PARP2 Activation in Cells using a Fluorescent Fusion Protein-based Reporter" app.jove.com/t/70497 @EMGSUS @BrownUCancer @BrownPathology